IL1B and COVID-19: Recognizing the role of pathological hyperinflammatory states in driving the development of COVID-19 and RA pathology, certain biological agents for RA treatment, such as IL-6 inhibitors (tocilizumab, sarilumab), IL-1 inhibitors (anakinra), TNF inhibitors (infliximab, adalimumab), and tsDMARDs like tofacitinib and baricitinib, may help improve COVID-19 outcomes.